CD4 and neoplasm: Vaccination against the most common H3K27 alteration, H3 K27M, induced mutation-specific CD4+ and CD8+ T cell responses in flank tumor models of DIPG, and a phase I clinical trial (NCT02960230) is ongoing to assess safety and efficacy of this vaccine in humans [121].